selpercatinib
eli lilly
 novel mechanism to ret inhibitor resistance --&gt; ntrk fusion ! validation of ntrk3 fusion as an acquired resistance mechanism to selpercatinib in ret fusion-positive #lungcancer #lcsm #nsclc #precisionmedicine 
Oncologist | Associate Prof | Executive Director-Research, MD Anderson Cancer Network | Medical Director, Clinical Center for Targeted Therapy. Tweets = my own.